TKThomas Kindler

Thomas Kindler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Kindler has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin H. Lee

    Authors' Affiliations: 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; 2Third Department of Medicine, Division of Hematology/Oncology/Pneumology; 3Institute of Pathology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; and 4Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland

    2 shared publications
  • D. Gary Gilliland

    Authors' Affiliations: 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; 2Third Department of Medicine, Division of Hematology/Oncology/Pneumology; 3Institute of Pathology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; and 4Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland

    2 shared publications
  • Andrea Schüler

    Authors' Affiliations: 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; 2Third Department of Medicine, Division of Hematology/Oncology/Pneumology; 3Institute of Pathology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; and 4Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland

    1 shared publication
  • Andreas Kreft

    Authors' Affiliations: 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; 2Third Department of Medicine, Division of Hematology/Oncology/Pneumology; 3Institute of Pathology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; and 4Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland

    1 shared publication
  • Claudia Scholl

    Division of Hematology, Department of Medicine, and

    1 shared publication
  • Daniel Sasca

    Authors' Affiliations: 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; 2Third Department of Medicine, Division of Hematology/Oncology/Pneumology; 3Institute of Pathology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; and 4Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland

    1 shared publication

Latest Publications

  • STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2

    by Winnie F. Tam, Patricia S. Hähnel, Andrea Schüler, Benjamin H. Lee, Rachel Okabe, Nan Zhu, Saskia V. Pante, Glen Raffel, Thomas Mercher, Gerlinde Wernig, et al.

    MOZ-TIF2 is a leukemogenic fusion oncoprotein that confers self-renewal capability to hematopoietic progenitor cells and induces acute myelogenous leukemia (AML) with long latency in bone marrow transplantation assays. Here, we report that FLT3-ITD transforms hematopoietic cells in cooperation with MOZ-TIF2 in vitro and in vivo. Coexpression of FLT3-ITD confers growth factor independent survival/proliferation, shortens disease latency, and results in an increase in the number of leukemic stem cells (LSC). We show that STAT5, a major effector of aberrant FLT3-ITD signal transduction, is both necessary and sufficient for this cooperative effect. In addition, STAT5 signaling is essential for MOZ-TIF2–induced leukemic transformation itself. Lack of STAT5 in fetal liver cells caused rapid differentiation and loss of replating capacity of MOZ-TIF2–transduced cells enriched for LSCs. Furthermore, mice serially transplanted with Stat5−/− MOZ-TIF2 leukemic cells develop AML with longer disease latency and finally incomplete penetrance when compared with mice transplanted with Stat5+/+ MOZ-TIF2 leukemic cells. These data suggest that STAT5AB is required for the self-renewal of LSCs and represents a combined signaling node of FLT3-ITD and MOZ-TIF2 driven leukemogenesis. Therefore, targeting aberrantly activated STAT5 or rewired downstream signaling pathways may be a promising therapeutic option. Cancer Res; 73(1); 373–84. ©2012 AACR.


  • Open Access

    K-RasG12D–induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to γ-secretase inhibitors

    by Thomas Kindler, Melanie G. Cornejo, Claudia Scholl, Jianing Liu, Dena S. Leeman, J. Erika Haydu, Stefan Fröhling, Benjamin H. Lee, D. Gary Gilliland

    To study the impact of oncogenic K-Ras on T-cell leukemia/lymphoma development and progression, we made use of a conditional K-RasG12D murine knockin model, in which oncogenic K-Ras is expressed from its endogenous promoter. Transplantation of whole bone marrow cells that express oncogenic K-Ras into wild-type recipient mice resulted in a highly penetrant, aggressive T-cell leukemia/lymphoma. The lymphoblasts were composed of a CD4/CD8 double-positive population that aberrantly expressed CD44. Thymi of primary donor mice showed reduced cellularity, and immunophenotypic analysis demonstrated a block in differentiation at the double-negative 1 stage. With progression of disease, approximately 50% of mice acquired Notch1 mutations within the PEST domain. Of note, primary lymphoblasts were hypersensitive to γ-secretase inhibitor treatment, which is known to impair Notch signaling. This inhibition was Notch-specific as assessed by down-regulation of Notch1 target genes and intracellular cleaved Notch. We also observed that the oncogenic K-Ras-induced T-cell disease was responsive to rapamycin and inhibitors of the RAS/MAPK pathway. These data indicate that patients with T-cell leukemia with K-Ras mutations may benefit from therapies that target the NOTCH pathway alone or in combination with inhibition of the PI3K/AKT/MTOR and RAS/MAPK pathways.